Research programme: haematological malignancies therapeutics - Janssen Biotech/Novera Therapeutics/OICR/UHN
Latest Information Update: 28 Nov 2019
At a glance
- Originator Novera Therapeutics; Ontario Institute for Cancer Research; University Health Network
- Developer Janssen Biotech; Novera Therapeutics; Ontario Institute for Cancer Research; University Health Network
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for research development in Haematological-malignancies in Canada
- 14 Oct 2015 Janssen Biotech enters into a research collaboration and option and license agreement with Novero Therapeutics, Ontario Institute for Cancer Research and University Health Network to co-develop therapeutics for Haematological malignancies
- 14 Oct 2015 Early research in Haematological malignancies in Canada (unspecified route)